Calcium channel blockers are associated with improved survival in pancreatic cancer patients undergoing neoadjuvant chemotherapy and resection
Open Access
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Ion Channels: New Actors Playing in Chemotherapeutic ResistanceCancers, 2019
- Calcium channel blockers use and overall survival in pancreatic cancer patients receiving gemcitabine.Journal of Clinical Oncology, 2017
- Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cellsInternational Journal of Oncology, 2016
- Drug repurposing in oncology—patient and health systems opportunitiesNature Reviews Clinical Oncology, 2015
- Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signalingOncotarget, 2015
- Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinomaWorld Journal of Gastrointestinal Pathophysiology, 2015
- Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinomaBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2014
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Blockage of Intermediate-Conductance Ca2+-Activated K+ Channels Inhibit Human Pancreatic Cancer Cell Growth in VitroMolecular Pharmacology, 2004